<DOC>
	<DOCNO>NCT02028949</DOCNO>
	<brief_summary>Unresectable , non-metastatic cirrhosis-related hepatocellular carcinoma ( HCC ) poor prognosis recommend curative treatment . Chemoembolisation widely use treatment patient , technique prove toxic . intrahepatic arterial chemotherapy lipiodol idarubicin could effective therapeutic approach , without deteriorate liver function . The rationale treatment resume follow : - HCC vascularise via hepatic artery system - The IHA perfusion anthracyclines lead high elimination via liver low systemic concentration - The absence embolisation reduces toxicity - toxiciity profile idarubicin well know drug widely use IV treatment leukemia - idarubicin cytotoxic drug tumor cell line . - The vitro cytotoxicity idarubicin 100 % low concentration - Lipiodol stay contact tumor tissue several week injection act vector drug - The idarubicin-lipiodol stable lipidol emulsion usually give intraarterial injection - The emulsion stable idarubicin anticancer molecule - Sequential inclusion accordance `` continual reassessment method '' make possible increase inclusion target toxicity level reduce inclusion dos low toxic The aim treatment improve survival .</brief_summary>
	<brief_title>Treatment Cirrhosis-related Hepatocellular Carcinoma With Intrahepatic Arterial Injection Emulsion Lipiodol Idarubicin ( ZavedosÂ® ) : Phase I Study</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Ethiodized Oil</mesh_term>
	<criteria>Inclusion criterion : Histologicallyproven hepatocellular carcinoma carcinoma meeting validate noninvasive criterion ( EASL , AASLD ) ChildPugh A OR B7 cirrhosis General health status WHO 0.1 Platelets &gt; 50 000/mm3 , Polynuclear neutrophils &gt; 1000/mm3 Creatininemia &lt; 1.5 time upper limit normal LVEF MUGA scan US &gt; 50 % Age &gt; 18 year Signed informed consent For woman childbearing age , effective mean contraception Exclusion criterion : Patients benefit curative treatment ( surgical resection , liver transplant treatment via percutaneous destruction ) Noncirrhotic liver Cirrhosis Child B8 B9 C Extrahepatic metastasis ( pulmonary micronodules &lt; 7mm consider contraindication ) Digestive hemorrhage within previous month Patient anticoagulant Pregnant woman Uncontrolled infection Hypersensitivity anthracyclines Hypersensitivity iodine contrast agent Patient guardianship ward court Patients already receive recommended cumulative dose anthracycline ( 93 mg/m2 idarubicin , 140 mg/m2 mitoxantrone , 550 mg/m2 doxorubicin , 600 mg/m2 daunorubicin , 900 mg/m2 epirubicin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
</DOC>